Cardiovascular Considerations During Cancer Therapy

IF 12 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Jacc: Cardiooncology Pub Date : 2024-12-01 DOI:10.1016/j.jaccao.2024.06.005

Darryl P. Leong MBBS, MPH, MBiostat, PhD , Sarah Waliany MD, MS , Husam Abdel-Qadir MD, PhD , Katelyn M. Atkins MD, PhD , Tomas G. Neilan MD, MPH , Ninian N. Lang MB ChB, PhD , Jennifer E. Liu MD , Anne H. Blaes MD, MS , Hira S. Mian MD , Heather N. Moore PharmD, BCOP, CPP , Ludhmila A. Hajjar MD , Alicia K. Morgans MD, MPH , Peter M. Ellis MBBS, MMed, PhD , Susan Dent MD

{"title":"Cardiovascular Considerations During Cancer Therapy","authors":"Darryl P. Leong MBBS, MPH, MBiostat, PhD , Sarah Waliany MD, MS , Husam Abdel-Qadir MD, PhD , Katelyn M. Atkins MD, PhD , Tomas G. Neilan MD, MPH , Ninian N. Lang MB ChB, PhD , Jennifer E. Liu MD , Anne H. Blaes MD, MS , Hira S. Mian MD , Heather N. Moore PharmD, BCOP, CPP , Ludhmila A. Hajjar MD , Alicia K. Morgans MD, MPH , Peter M. Ellis MBBS, MMed, PhD , Susan Dent MD","doi":"10.1016/j.jaccao.2024.06.005","DOIUrl":null,"url":null,"abstract":"<div><div>The administration of certain cancer therapies can be associated with the development of cardiovascular toxicity or complications. This spectrum of toxicities is broad and requires nuanced approaches for prevention, identification, and management. This expert panel summarizes the consensus of opinions of diverse health care professionals in several key areas: 1) cardioprotection involves strategies aimed at the primary prevention of cancer therapy–related cardiovascular toxicity; 2) surveillance entails monitoring for cancer therapy–related cardiovascular toxicity during cancer therapy; 3) permissive cardiotoxicity is the informed continuation of cancer therapy in the presence of cardiovascular toxicity, along with the implementation of mitigating cardiovascular treatments; and 4) special considerations include the invasive management of severe cardiovascular disease in patients receiving treatments for advanced cancer and the exploration of drug-drug interactions in cardio-oncology. In this expert panel, we also highlight gaps in evidence in an effort to continue to advance science in the cardiovascular care of our patients undergoing cancer therapy.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 6","pages":"Pages 815-834"},"PeriodicalIF":12.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11711816/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jacc: Cardiooncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266608732400348X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

The administration of certain cancer therapies can be associated with the development of cardiovascular toxicity or complications. This spectrum of toxicities is broad and requires nuanced approaches for prevention, identification, and management. This expert panel summarizes the consensus of opinions of diverse health care professionals in several key areas: 1) cardioprotection involves strategies aimed at the primary prevention of cancer therapy–related cardiovascular toxicity; 2) surveillance entails monitoring for cancer therapy–related cardiovascular toxicity during cancer therapy; 3) permissive cardiotoxicity is the informed continuation of cancer therapy in the presence of cardiovascular toxicity, along with the implementation of mitigating cardiovascular treatments; and 4) special considerations include the invasive management of severe cardiovascular disease in patients receiving treatments for advanced cancer and the exploration of drug-drug interactions in cardio-oncology. In this expert panel, we also highlight gaps in evidence in an effort to continue to advance science in the cardiovascular care of our patients undergoing cancer therapy.

查看原文本刊更多论文

癌症治疗中的心血管因素：证据和JACC的差距：心血管肿瘤学专家小组的建议。

使用某些癌症疗法可能会引起心血管毒性或并发症。这种毒性的范围很广，需要细致入微的预防、识别和管理方法。本专家小组总结了不同医护人员在几个关键领域的共识：1）心脏保护涉及癌症治疗相关心血管毒性的一级预防策略；2）监测包括在癌症治疗过程中监测癌症治疗相关心血管毒性；3）允许性心脏毒性是指在知情的情况下继续进行癌症治疗，同时实施减轻心血管毒性的治疗方法；4）特殊考虑包括对接受晚期癌症治疗的严重心血管疾病患者进行侵入性管理，以及探索心肿瘤学中的药物相互作用。在本专家小组中，我们还强调了证据方面的差距，以继续推进对接受癌症治疗的患者进行心血管治疗的科学研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Jacc: Cardiooncology Multiple-

CiteScore

12.50

自引率

6.30%

发文量

106

期刊介绍： JACC: CardioOncology is a specialized journal that belongs to the esteemed Journal of the American College of Cardiology (JACC) family. Its purpose is to enhance cardiovascular care for cancer patients by publishing high-quality, innovative scientific research and sharing evidence-based knowledge. The journal aims to revolutionize the field of cardio-oncology and actively involve and educate professionals in both cardiovascular and oncology fields. It covers a wide range of topics including pre-clinical, translational, and clinical research, as well as best practices in cardio-oncology. Key areas of focus include understanding disease mechanisms, utilizing in vitro and in vivo models, exploring novel and traditional therapeutics (across Phase I-IV trials), studying epidemiology, employing precision medicine, and investigating primary and secondary prevention. Amyloidosis, cardiovascular risk factors, heart failure, and vascular disease are some examples of the disease states that are of particular interest to the journal. However, it welcomes research on other relevant conditions as well.